CA2535506A1 - Pharmaceutical compositions for preventing breast and ovarian cancer - Google Patents

Pharmaceutical compositions for preventing breast and ovarian cancer Download PDF

Info

Publication number
CA2535506A1
CA2535506A1 CA002535506A CA2535506A CA2535506A1 CA 2535506 A1 CA2535506 A1 CA 2535506A1 CA 002535506 A CA002535506 A CA 002535506A CA 2535506 A CA2535506 A CA 2535506A CA 2535506 A1 CA2535506 A1 CA 2535506A1
Authority
CA
Canada
Prior art keywords
selenium
composition
breast
brca1
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002535506A
Other languages
English (en)
French (fr)
Inventor
Jan Lubinsky
Steven Narod
Stanislaw Zajaczek
Elzbieta Kowalska
Bohdan Gorski
Tomasz Huzarski
Tomasz Byrski
Jacek Gronwald
Jowita Huzarska
Barbara Gawronska-Szklarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pomeranian Academy of Medicine
Original Assignee
Pomeranian Academy of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pomeranian Academy of Medicine filed Critical Pomeranian Academy of Medicine
Publication of CA2535506A1 publication Critical patent/CA2535506A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
CA002535506A 2003-08-11 2004-08-10 Pharmaceutical compositions for preventing breast and ovarian cancer Abandoned CA2535506A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.361597 2003-08-11
PL361597A PL214402B1 (pl) 2003-08-11 2003-08-11 Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
PCT/PL2004/000063 WO2005013951A2 (en) 2003-08-11 2004-08-10 Pharmaceutical compositions for preventing breast and ovarian cancer

Publications (1)

Publication Number Publication Date
CA2535506A1 true CA2535506A1 (en) 2005-02-17

Family

ID=34132453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002535506A Abandoned CA2535506A1 (en) 2003-08-11 2004-08-10 Pharmaceutical compositions for preventing breast and ovarian cancer

Country Status (10)

Country Link
EP (1) EP1660060A2 (pl)
JP (1) JP2007502270A (pl)
KR (1) KR20060066719A (pl)
CN (1) CN1835740A (pl)
AU (1) AU2004263070A1 (pl)
CA (1) CA2535506A1 (pl)
EA (1) EA200600386A1 (pl)
PL (1) PL214402B1 (pl)
WO (1) WO2005013951A2 (pl)
ZA (1) ZA200602081B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032074A1 (en) * 2004-09-21 2006-03-30 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of cancer
US20110117545A1 (en) * 2007-03-26 2011-05-19 Decode Genetics Ehf Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CN100548311C (zh) 2007-06-13 2009-10-14 中国科学技术大学 硒代硫酸钠在制备临床补硒和治疗癌症药物中的应用及快速制备方法
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
US20110105342A1 (en) * 2008-03-13 2011-05-05 Jan Lubinski Method for determining reduced predisposition to cancer based on genetic profile
KR101026291B1 (ko) * 2008-06-30 2011-03-31 주식회사 태강 SeO2 doped W-Mo-Li 화합물을 함유한 항암제 조성물
GB0916010D0 (en) * 2009-09-11 2009-10-28 Isis Innovation JMJD2 demethylase inhibitors
WO2012067525A1 (en) 2010-11-18 2012-05-24 Pomorski Uniwersytet Medyczny Genotypes and selenium level as a markers of breast/ovarian cancer risk in brca1 mutation carriers
JP5895303B2 (ja) * 2011-04-01 2016-03-30 イアソマイ エービー Ｎ−アセチル−ｌ−システインを含む新規な組み合わせおよびその使用
SG10202101918RA (en) * 2013-03-15 2021-03-30 Alltech Inc Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
BR112016020233B1 (pt) * 2014-03-14 2022-07-19 Alltech Inc. Composições de compostos seleno orgânicos e seus usos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19825746A1 (de) * 1998-06-09 1999-12-16 Biosyn Arzneimittel Gmbh Kombination von Selen-haltigen Verbindungen mit Zytostatika

Also Published As

Publication number Publication date
AU2004263070A1 (en) 2005-02-17
JP2007502270A (ja) 2007-02-08
CN1835740A (zh) 2006-09-20
WO2005013951A2 (en) 2005-02-17
EP1660060A2 (en) 2006-05-31
KR20060066719A (ko) 2006-06-16
EA200600386A1 (ru) 2006-12-29
WO2005013951A3 (en) 2005-09-15
PL361597A1 (pl) 2005-02-21
PL214402B1 (pl) 2013-07-31
ZA200602081B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
ZA200602081B (en) Pharmaceutical compositions for preventing breast and ovarian cancer
Prasad Zinc: an antioxidant and anti-inflammatory agent: role of zinc in degenerative disorders of aging
Prasad et al. Zinc in cancer prevention
Mariani et al. Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects
Ou et al. Role and mechanism of ferroptosis in neurological diseases
KR102090836B1 (ko) 세포 정제를 촉진하기 위한 경구 제제
Killilea et al. Mineral requirements for mitochondrial function: A connection to redox balance and cellular differentiation
AU715430B2 (en) Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
US20050069594A1 (en) Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
Dresen et al. Overview of oxidative stress and the role of micronutrients in critical illness
Feng et al. Radioprotective effect of lactoferrin in mice exposed to sublethal X‑ray irradiation
Kumar et al. Zinc deficiency and its effect on the brain: an update
Galchenko et al. Association of microelementos with the risk of hypochromic anemia in vegetarians and vegans
MXPA06001632A (en) Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
Chaitanya et al. Mineral Deficiencies: a root cause for reduced longevity in mammals
Hurley et al. Trace elements in man and animals 6
Guarnieri et al. Muscle cathepsin D activity, and RNA, DNA and protein content in maintenance hemodialysis patients
Braverman et al. Essential trace elements and cancer
Prasad Clinical and immunological effects and biomarkers of zinc deficiency
RU2557527C1 (ru) Способ коррекции иммунобиохимического статуса у коров в предродовом и послеродовом периодах
Khail et al. Effect of N-acetylcysteine on total oxidant status in children with β-thalassemia major
EP4032537A1 (en) Composition for elongating telomeres
Buttriss et al. A review of the MAFF Optimal Nutrition Status research programme: folate, iron and copper
Srivastava et al. One advantageous reflection of iron metabolism in context of normal physiology and pathological phases
Pushparani Serum zinc and iron level in type 2 diabetes mellitus with periodontitis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued